Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BSEM NASDAQ:ERAS NASDAQ:IVA NASDAQ:LXRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSEMBioStem Technologies$6.38+6.9%$10.86$5.02▼$28.26$106.84M-0.2965,457 shs68,234 shsERASErasca$1.58-1.3%$1.49$1.01▼$3.31$448.20M1.071.36 million shs396,165 shsIVAInventiva$5.23+13.9%$3.49$1.53▼$5.51$500.30M0.7318,599 shs125,673 shsLXRXLexicon Pharmaceuticals$1.13-0.9%$1.05$0.28▼$2.18$410.64M1.178.42 million shs1.41 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSEMBioStem Technologies+3.83%-7.87%-48.73%-48.73%-48.67%ERASErasca+0.63%+5.26%-8.05%+45.45%-44.83%IVAInventiva-1.50%+2.91%+46.46%+39.30%+91.25%LXRXLexicon Pharmaceuticals+0.88%-1.72%+3.64%+63.00%-35.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSEMBioStem TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AERASErasca2.1333 of 5 stars3.41.00.00.01.92.50.6IVAInventiva3.1183 of 5 stars3.45.00.00.02.21.70.6LXRXLexicon Pharmaceuticals2.5978 of 5 stars3.33.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSEMBioStem Technologies 0.00N/AN/AN/AERASErasca 2.86Moderate Buy$4.29171.25% UpsideIVAInventiva 2.83Moderate Buy$13.00148.57% UpsideLXRXLexicon Pharmaceuticals 2.50Moderate Buy$3.23185.40% UpsideCurrent Analyst Ratings BreakdownLatest BSEM, ERAS, IVA, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025IVAInventivaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$26.008/18/2025ERASErascaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$4.00 ➝ $2.008/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.20 ➝ $1.906/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSEMBioStem Technologies$301.83M0.35N/AN/AN/A∞ERASErascaN/AN/AN/AN/A$1.31 per shareN/AIVAInventiva$9.95M50.28N/AN/A($1.21) per share-4.32LXRXLexicon Pharmaceuticals$58.43M7.03N/AN/A$0.36 per share3.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSEMBioStem TechnologiesN/A$1.145.602.79N/AN/AN/AN/A11/11/2025 (Estimated)ERASErasca-$161.65M-$0.45N/AN/AN/AN/A-31.19%-26.34%11/11/2025 (Estimated)IVAInventiva-$199.34MN/A0.00N/AN/AN/AN/AN/A9/25/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)Latest BSEM, ERAS, IVA, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ERASErasca-$0.12-$0.12N/A-$0.12N/AN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSEMBioStem TechnologiesN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AIVAInventivaN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSEMBioStem TechnologiesN/AN/AN/AERASErascaN/A11.0311.04IVAInventivaN/A0.920.92LXRXLexicon Pharmaceuticals0.434.164.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSEMBioStem TechnologiesN/AERASErasca67.78%IVAInventiva19.06%LXRXLexicon Pharmaceuticals74.70%Insider OwnershipCompanyInsider OwnershipBSEMBioStem TechnologiesN/AERASErasca14.40%IVAInventiva32.00%LXRXLexicon Pharmaceuticals13.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSEMBioStem TechnologiesN/A16.75 millionN/AN/AERASErasca120283.67 million242.82 millionOptionableIVAInventiva10095.66 million65.05 millionNot OptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableBSEM, ERAS, IVA, and LXRX HeadlinesRecent News About These CompaniesLexicon Pharmaceuticals to Participate at Two Upcoming Investor ConferencesAugust 27 at 8:30 AM | globenewswire.comLexicon Pharmaceuticals: Strategic Retrenchment Likely To Take Years To Show ResultsAugust 25 at 12:10 AM | seekingalpha.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200-Day Moving Average - What's Next?August 20, 2025 | marketbeat.comLeerink Partnrs Brokers Increase Earnings Estimates for LXRXAugust 11, 2025 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Raised to $1.90 at CitigroupAugust 8, 2025 | marketbeat.comLexicon (LXRX) Upgraded to Buy: Here's What You Should KnowAugust 8, 2025 | zacks.comBalanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue ChallengesAugust 8, 2025 | tipranks.comLexicon Pharmaceuticals Reports Strong Q2 2025 ResultsAugust 7, 2025 | msn.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.comLexicon Pharmaceuticals (LXRX): Citigroup Raises Price Target, Maintains Buy Rating | LXRX ...August 7, 2025 | gurufocus.comQ2 2025 Lexicon Pharmaceuticals Inc Earnings Call TranscriptAugust 6, 2025 | gurufocus.comLexicon Pharmaceuticals, Inc. (LXRX) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comLexicon Pharmaceuticals (LXRX) Reports Strong Q2 Financial TransformationAugust 6, 2025 | gurufocus.comLexicon Pharmaceuticals Inc (LXRX) Reports Q2 2025 Earnings: EPS of $0. ...August 6, 2025 | gurufocus.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6, 2025 | gurufocus.comLexicon Pharmaceuticals (LXRX) Surpasses Q2 Earnings ExpectationsAugust 6, 2025 | gurufocus.comLexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top EstimatesAugust 6, 2025 | zacks.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business ...August 6, 2025 | gurufocus.comLexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 6, 2025 | globenewswire.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Average Rating of "Hold" by BrokeragesAugust 4, 2025 | marketbeat.comLexicon Pharmaceuticals (LXRX) Projected to Post Earnings on WednesdayJuly 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025Post-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?By Nathan Reiff | August 11, 2025BSEM, ERAS, IVA, and LXRX Company DescriptionsBioStem Technologies OTCMKTS:BSEM$6.38 +0.41 (+6.87%) As of 03:59 PM EasternBioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.Erasca NASDAQ:ERAS$1.58 -0.02 (-1.25%) Closing price 04:00 PM EasternExtended Trading$1.58 +0.00 (+0.32%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Inventiva NASDAQ:IVA$5.23 +0.64 (+13.94%) Closing price 04:00 PM EasternExtended Trading$5.28 +0.05 (+0.96%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Lexicon Pharmaceuticals NASDAQ:LXRX$1.13 -0.01 (-0.88%) Closing price 04:00 PM EasternExtended Trading$1.14 +0.02 (+1.33%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Williams-Sonoma Q2 Results Prove Its Buy-and-Hold Quality Okta: Market Comes to a Boil, Explosive Upside Is Possible MongoDB Roars Back to Life: It’s Not Too Late to Buy More Vertical Aerospace: An Analyst's Roadmap to a Potential Re-Rating AEHR Spikes 36% on Hyperscaler Order—Investors Should Take Notice From Debt to Liftoff: EchoStar's $23 Billion Catalyst Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access